Back to Search
Start Over
Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2021 Jun; Vol. 62 (6), pp. 1510-1513. Date of Electronic Publication: 2021 Jan 24. - Publication Year :
- 2021
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 62
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Editorial & Opinion
- Accession number :
- 33491527
- Full Text :
- https://doi.org/10.1080/10428194.2021.1876869